Minimal Residual Disease Detection:
Key Considerations for Clinical Development
About This EventMeasurement of residual disease is the best predictor of treatment outcome for leukemia, lymphoma, and myeloma. First found to be of great value in monitoring chronic myelogenous leukemia, it has become generally useful across other types of leukemia and lymphoma, and has become essential in monitoring, modifying, and reinitiating therapeutic intervention. It has also brought about a new definition of remission based on the detection and measurement of defined levels of residual malignant cells. Although the value of minimal residual disease (MRD) measurement is well defined, the best technical approach can be variable based on a number of factors. Please join Q2 Solutions as we explore the current landscape of MRD detection, key considerations for each approach, as well as current advancements on the horizon.
Key topics covered in this webinar:
- Clinical background and current guidelines for MRD measurement
- Overview of current technologies and methods for MRD detection, including input material, sensitivities, general turnaround times, costs, and more.
- Key considerations for choosing the right MRD detection approach
- Recent advancements and the future of MRD detection in clinical development
Scientific Advisor, Flow Cytometry
Mark Edinger is the scientific advisor for Flow Cytometry at Q2 Solutions. As the scientific advisor, Mark is responsible for flow cytometry assay design and implementation. He works with both the Translational Biomarkers Laboratory to develop assays and the Global Cytometry Group to produce assays, and is the architect of the systems and workflows used in Q2 Solutions’ flow cytometry assay development and production laboratories.
Mark began his career at the Cleveland Clinic Foundation, a preeminent medical institution, where he pioneered flow cytometry in the late 1970s, building both clinical and research core flow cytometry laboratories. During his 21 years at the Cleveland Clinic, Mark developed many of the techniques and assays employed today for clinical practice and academic research. During this time, Mark also was a consultant for Becton Dickinson (BD) Immunocytometry Systems and participated in clinical trials of new BD products. In 1998, Mark formally joined BD where he founded the Technical Applications Group, and later the R&D Systems Validation Laboratory. While at BD, Mark, working with scientists at Amgen, developed the whole blood phosphoprotein lysing buffer that is now used daily in laboratories throughout the world. Mark joined Quintiles in 2012 and has been part of a collaboration which introduced the quantitative standardization of flow cytometers, along with other state of the art practices, making Quintiles flow laboratories the first to offer this level of instrument standardization anywhere in the world. Mark became part of the Q2 Solutions team when the company was officially launched in June 2015 as a result of a Quintiles and Quest Diagnostics joint venture.
Mark graduated from Case Western Reserve University with a Bachelor of Science degree in Biology.
Senior Director and Global Head, Translational Genomics
Patrick Hurban, Ph.D. is senior director and global head of Translational Genomics at Q2 Solutions. In this role, he is responsible for the identification and implementation of new genomic capabilities, encompassing bioinformatics and wet-laboratory methods, as well as the development and validation of genomic assays to support research and clinical programs. These include broad-based screening assays, such as exome and RNA sequencing, to highly focused expression, genotyping and sequencing assay panels that target a smaller number of genes.
Dr. Hurban has more than 25 years of experience in molecular genetics, including more than 18 years in positions of increasing responsibility in high-profile genomics-focused organizations. His research interests have focused on the genetic control of gene expression and have spanned diverse fields such as toxicology, developmental, and cancer biology.
Following a Bachelor’s degree in Biology from the University of North Carolina at Chapel Hill, he earned his Ph.D. in Human Genetics from the University of Utah in Salt Lake City before serving as a postdoctoral research fellow of the American Cancer Society in the Department of Developmental Biology at Stanford University.
Director of Hematopathology
Dr. Franklin Sedarat is board certified in anatomic pathology, clinical pathology, and hematology. Dr. Sedarat has more than 10 years of experience in hematopathology and oncological pathology, with a long track record as consultative
diagnostician in hematopathology. Prior to coming to Q2 Solutions, he served in multiple national reference labs including Integrated Oncology/LabCorp, Genzyme Genetics, and Genoptix. Dr. Sedarat has published in multiple peer reviewed journals and has presented in various national and international conferences.
As director of hematopathology at Q2 Solutions, Dr. Sedarat Oversees anatomic pathology and hematopathology clinical operations and testing in Valencia, ensures laboratory operations meet or exceed all applicable regulatory requirements, and that the highest standards of customer service, quality and safety standards are maintained. As a principal investigator, he supports multiple clinical trials and companion diagnostics studies.